αKG	alpha-ketoglutarate
AML	acute myeloid leukemia
b.i.d.	bis in die, two times a day
CTCAE	common terminology criteria for adverse events
ctDNA	circulating tumor DNA
D-2HG	D-2-hydroxyglutarate
DLT	dose-limiting toxicity
ETC	electron transport chain
IDH1/2	isocitrate dehydrogenase 1 or 2
IDH1/2WT	IDH1/2 wild-type
IDH1/2MT	IDH1/2 mutant
MAD	maximum administered dose
MRS	magnetic resonance spectroscopy
MS	mass spectrometry
MTD	maximum tolerated dose
NGS	next-generation sequencing
q.d.	quaque die, one a day
RANO	response assessment in neuro-oncology
RD	recommended dose (for a phase II clinical trial)
RECIST	response evaluation criteria in solid tumors
SAE	serious adverse events
T2DM	type 2 diabetes mellitus
TCA cycle	tricarboxylic acid cycle